Recent press releases

3 November 2003

Lectus Therapeutics Ltd announces financing from the SULIS Seedcorn Fund

Lectus Therapeutics Limited (‘LTL’), an emerging UK-based bio-pharmaceutical company, today announced it had closed a deal for seed financing from the SULIS Seedcorn fund. LTL’s vision is to become a world leader in developing ion channel therapeutics with an enhanced safety profile.

LTL will exploit the power of its proprietary functional proteomics platform, LEPTICSTM (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and build on its knowledge of ion channels and protein-protein interactions, to develop next-generation ion channel modulators.

Roland Kozlowski, CEO of LTL, said, “Lectus Therapeutics has received its seed financing in a difficult market, which highlights the potential value of proteomics for the discovery of novel drugs that work on ion channels.”

Iain Wilcock, Investment Manager for SULIS commented, “We are delighted to have the opportunity to work with Lectus Therapeutics as they move forward in developing their business. This is a perfect example of the type of company our university challenge funds seek to support.”

 Download this press release

© Lectus Therapeutics Ltd. 2003–2010